Internship

MBA Intern

Finance

Posted on 10/30/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Cambridge, MA, USA

70/30 work model requires 70% in-office presence.

Category
Strategy Development
Business Development
Business & Strategy
Requirements
  • Currently enrolled as a 1st year in a full-time MBA program (planned graduation in Spring 2026)
  • 4+ years experience pre-MBA in healthcare consulting, pharma, biotech, or similar experience in a professional services or investment capacity (e.g., management or strategy consulting, investment banking, private equity, or venture capital)
Responsibilities
  • The Corporate Finance Team is responsible for driving the financial planning process for the company, leading the consolidation of financial statements, financial reporting, and overall budgeting and forecasting processes.
  • The team also provides strategic financial forecasting support, cash flow management, executive decision and communication support, and drives cross-functional initiatives across the finance organization.
  • The Corporate Development team is responsible for driving strategic transactions and long-term planning, focusing on initiatives that enhance the company’s technology and expand its pipeline and portfolio.
  • This includes M&A, partnerships, and licensing deals.
  • The team also collaborates cross-functionally, driving strategic projects alongside commercial, R&D, and CMC teams to support the company’s growth and innovation objectives.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the speed and efficiency of drug discovery and manufacturing. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of health conditions.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

15%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE